# Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction

Study · id `cardio:ct-nct07445737` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07445737](<https://clinicaltrials.gov/study/NCT07445737>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07445737

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 700 participants.

## Technical summary

Registry record NCT07445737. Randomized; no masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2029-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 700 participants (planned count; ClinicalTrials.gov record NCT07445737, source copy `cardio:ctgov-nct07445737-2026-03-03`, retrieved 2026-10-26)
- Planned start: 2026-06 (anticipated) (ClinicalTrials.gov record NCT07445737, source copy `cardio:ctgov-nct07445737-2026-03-03`, retrieved 2026-10-26)
- Primary completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07445737, source copy `cardio:ctgov-nct07445737-2026-03-03`, retrieved 2026-10-26)
- Completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07445737, source copy `cardio:ctgov-nct07445737-2026-03-03`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT07445737, source copy `cardio:ctgov-nct07445737-2026-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07445737-2026-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction
- Acronym: MAMI
- Condition: STEMI - ST Elevation Myocardial Infarction
- Intervention (Drug): Methoxyflurane
- Intervention (Drug): Morphine
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Medical Developments International Limited
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 1b302a76f8396fad7e97c98bf40ba4961e03624303c5fa084aad31522fffba63
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
